20 Results for "

GD2

" in MedChemExpress (MCE) Product Catalog:
Products (20)

20 Results for "GD2" in MCE Product Catalog:

Cat. No.: HY-P9933
CAS No.: 1363687-32-4
Synonyms: APN-311; Ch14.18; MAb-14.18

Target:  

Apoptosis PERK mTOR

Domaines de recherche:  

Cancer

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer [2] .
loading...
    loading...
Cat. No.: HY-165740
CAS No.: 65988-71-8
Synonyms: Disialoganglioside GD2
Target:  

Apoptosis

Domaines de recherche:  

Cancer

Ganglioside GD2 (Disialoganglioside GD2) is a tumor-associated antigen. Ganglioside GD2 shows limited expression in normal tissues but is overexpressed in multiple tumor types, and thus can serve as a target in cancer. Ganglioside GD2 is associated with tumor development and malignant phenotypes, and its mechanism of action relies on enhancing cell proliferation, motility, migration, adhesion and invasion, with specific effects depending on the tumor type [2].
loading...
    loading...
Cat. No.: HY-P99206
CAS No.: 1879925-92-4
Synonyms: Naxitamab-gqgk; Humanized 3F8; Hu3F8

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Neurological Disease Cancer

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers .
loading...
    loading...
Cat. No.: HY-P990845

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Cancer

Anti-Ganglioside GD2 Antibody (14G2a) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human Ganglioside GD2. Anti-Ganglioside GD2 Antibody (14G2a) can induce neuroblastoma cells autophagy and lysis. Anti-Ganglioside GD2 Antibody (14G2a) can be used for the research of cancer, such as neuroblastoma [2].
loading...
    loading...
Cat. No.: HY-158109
Pureté:  99.39%
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .
loading...
    loading...
Cat. No.: HY-P99757
CAS No.: 2278244-14-5
Synonyms: Hu3F8-BsAb

Target:  

CD3

Domaines de recherche:  

Cancer

Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma [2] .
loading...
    loading...
Cat. No.: HY-P991040
Synonyms: Gamsitabart; M3554 Antibody

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Cancer

hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
loading...
    loading...
Cat. No.: HY-N16333
CAS No.: 154463-60-2
Category:  

Lipids

C18:0 GD2 Ceramide (d18:1/18:0) is a ganglioside .
loading...
    loading...
Cat. No.: HY-167596S
C18:0-d7 GD2 Ceramide (d18:1/18:0-d7) is deuterium labeled C18:0 GD2 Ceramide (d18:1/18:0) .
loading...
    loading...
Cat. No.: HY-N15811
CAS No.: 497863-25-9
Category:  

Lipids

GD2 Sphingosine (d18:1) is a sphingolipid.
loading...
    loading...
Cat. No.: HY-P99206A
CAS No.: 1879925-92-4

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Cancer

Naxitamab (Hu3F8) (Mouse IgG1) is a mouse-derived IgG1 monoclonal antibody targeting the diazoglycoside GD2 (hu3F8). Naxitamab can be used in the research of neuroblastoma, osteosarcoma, and other GD2-positive cancers .
loading...
    loading...
Cat. No.: HY-N15776
CAS No.: 3077081-43-4
Category:  

Lipids

C24:1 GD2 Ceramide (d18:1/24:1) is a sphingoid base linked to a fatty acid. C24:1 GD2 Ceramide (d18:1/24:1) interacts with other membrane lipids and allows GD2 to be tightly anchored to the cell surface .
loading...
    loading...
Cat. No.: HY-E70049
CAS No.: 67338-98-1
Synonyms: GM2/GD2 synthase
Target:  

Others

Domaines de recherche:  

Neurological Disease

beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) (GM2/GD2 synthase) is a key enzyme which catalyzes the conversion of GM3, GD3 and lactosylceramide (LacCer) to GM2, GD2 and asialo-GM2 (GA2), respectively. beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) is a key enzyme to control the synthesis of brain-enriched complex gangliosides .
loading...
    loading...
Cat. No.: HY-P991585

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Cancer

MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
loading...
    loading...
Cat. No.: HY-P990076
CAS No.: 2131168-99-3
Synonyms: APN-301; hu14.18-IL2; EMD 273063

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Cancer

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .
loading...
    loading...
Cat. No.: HY-P991131
CAS No.: 3011830-62-6

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Cancer

Daretabart is a humanized IgG1K antibody targeting GD2, which can be used for anti-tumor research. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-174418
CAS No.: 2097522-37-5
NM600 is an alkylphosphocholine mimetic RPT agent. NM600 demonstrates an antitumor activity against a second GD2+ neuroblastoma xenograft model with SY5Y cells. NM600 can enhance suboptimal CAR T cell efficacy against solid tumors. NM600 can be studied in research for neuroblastoma .
loading...
    loading...
Cat. No.: HY-P992317

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Inflammation/Immunology Cancer

ATL301 is a human monoclonal antibody that targets human ganglioside GD2 (ganglioside GD2). GD2 is a highly expressed glycolipid antigen on the surface of neuroepithelial tumor cells, and is commonly found in neuroblastoma, melanoma, osteosarcoma, small cell lung cancer, etc.
loading...
    loading...
Cat. No.: HY-P990916
CAS No.: 2888594-15-6

Target:  

Inhibitory Antibodies

Domaines de recherche:  

Inflammation/Immunology

HY-P990916 is an ganglioside GD2-targeting IgG1κ type chimeric humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-181911
Domaines de recherche:  

Neurological Disease

L2-FK866 is an ADC payload-linker conjugate (Drug-linker conjugate for ADC). L2-FK866 contains the ADC linker (Val-Cit-p-aminobenzyl) and the NAMPT inhibitor FK866 (HY-50876). L2-FK866 can be conjugated with Dinutuximab (HY-P9933) to form an ADC. L2-FK866 is applicable to neuroblastoma research .
loading...
    loading...
  • 1